Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

(2019) Nicholas C. Turner et al.   JOURNAL OF CLINICAL ONCOLOGY

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

(2019) et al.   JAMA Oncology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of pharmacogenetics in capecitabine efficacy and toxicity

(2016) S.W. Lam et al.   CANCER TREATMENT REVIEWS

Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial

(2016) Tsutomu Takashima et al.   LANCET ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Roles for miRNAs in endocrine resistance in breast cancer

(2015) Penn Muluhngwi et al.   ENDOCRINE-RELATED CANCER

Quantitative assessment of appearance changes and related distress in cancer patients

(2013) Keiko Nozawa et al.   PSYCHO-ONCOLOGY

Endocrine resistance in breast cancer: Current status and a perspective on the roles of miRNAs (Review)

(2013) JICHUN ZHOU et al.   Oncology Letters

Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues

(2012) Takeshi Hirota et al.   LUNG CANCER

Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer

(2011) Tokiko Ito et al.   BREAST CANCER RESEARCH AND TREATMENT

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

(2011) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-line chemotherapy with or without biologic agents for metastatic breast cancer

(2010) Claudia Andreetta et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer

(2009) Junichi Kurebayashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Contemporary issues and the potential uses of capecitabine in metastatic breast cancer

(2009) Peter Barrett-Lee et al.   CANCER TREATMENT REVIEWS